Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISLB 2022 | The role of liquid biopsy in cancer monitoring

Eloisa Jantus-Lewintre • 17 Oct 2022
ISLB 2022
General

Eloisa Jantus-Lewintre, PhD, Universitat Politècnica De València, Valencia, Spain, discusses the great potential of liquid biopsy in cancer detection, monitoring, and treatment. Dr Jantus-Lewintre also discusses the use of liquid biopsy as a prognostic and predictive tool for patients receiving targeted therapy or immunotherapy, as well as for the assessment of minimal residual disease (MRD) status.
This interview took place at the International Society of Liquid Biopsy (ISLB) 2022 congress in Miami, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eloisa Jantus-Lewintre

1:47
Selecting the best method of liquid biopsy for different cancers
Eloisa Jantus-Lewintre • 17 Oct 2022
1:28
Current limitations of liquid biopsy
Eloisa Jantus-Lewintre • 17 Oct 2022

Related Videos

0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
3:10
PALOMA: subcutaneous amivantamab in advanced solid tumors
Natasha Leighl • 17 Apr 2024
The content of VJOncology is intended for healthcare professionals